Subscribe To
Tg therapeutics to participate in the 5th annual guggenheim inflammation, neurology & immunology (ini) conference
Fireside chat scheduled for Monday, November 6, 2023, at 3:10 PM ET NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX) ...
November 3, 2023, 11:30 am
Hillevax to present at upcoming investor conferences
BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commerci...
November 1, 2023, 4:48 pm
Masonic cancer center, university of minnesota to present data in poster presentation human data readout for phase 1 study to evaluate hcw9218 in solid tumors at sitc 38th annual meeting
HCW9218 is the lead product candidate of HCW Biologics Inc. MIRAMAR, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or...
November 1, 2023, 11:30 am
Outlook therapeutics® to present at guggenheim's 5th annual inflammation, neurology & immunology (ini) conference
Live audio webcast fireside chat on Tuesday, November 7th at 1:50 PM ET Live audio webcast fireside chat on Tuesday, November 7th at 1:50 PM ET...
November 1, 2023, 8:05 am
Zyversa therapeutics announces research published in the peer-reviewed journal diabetes reinforcing ic 100’s rationale for inhibiting asc to attenuate damaging inflammation associated with serious con
Paper reports that obesity exacerbates scarring of the heart’s muscular tissue (myocardial fibrosis) through recruitment of inflammasome ASC to the ...
October 25, 2023, 10:50 am
Dupixent® (dupilumab) phase 3 results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (eoe)
Late-breaking presentation at ACG 2023 showed histologic and endoscopic improvements were maintained with no new safety signals to week 52 with higher...
October 22, 2023, 6:59 pm
Eli lilly stock hits new high on positive crohn's disease study results
Eli Lilly and Co (NYSE:LLY) announced on Thursday that its drug development candidate, mirikizumab, met the main goals of a late-stage study to test...
October 12, 2023, 8:35 am
Cardiol therapeutics says study results show positive effects of subcutaneously administered cannabidiol
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) has reported positive study results showing that cannabidiol, the active pharmaceutical ingredient in the...
October 10, 2023, 8:15 am
Gri bio announces publication of comprehensive invariant nkt (inkt) cell review in frontiers in immunology demonstrating a key role of type 1 inkt cells in modulating various fibrotic conditions
In several murine models of chronic inflammation and fibrosis, as well as in humans, it has been shown ...
October 5, 2023, 12:45 pm
Zyversa therapeutics’ ceo, stephen c. glover to participate in panel at the bioflorida conference discussing inflammation and its impact on numerous diseases
Mr. Glover will also serve as a judge in BioPitch competition for life science companies seeking seed and early-stage investment. ZyVersa is advancing...
September 27, 2023, 11:07 am
Galectin therapeutics to present update on its belapectin liver cirrhosis program at the 20th edition of discovery on target meeting, in boston, september 25-28, 2023
NORCROSS, Ga., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target gale...
September 26, 2023, 8:00 am
Dupixent® (dupilumab) sbla for treatment of eosinophilic esophagitis (eoe) in children aged 1 to 11 accepted for fda priority review
If approved, Dupixent would be the first and only treatment in the U.S. indicated for children aged 1 to 11 with EoE, a disease driven by type 2
September 26, 2023, 5:29 am
Week in review: everest acquires novel autoimmune therapy in $132 million agreement
Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a...
September 24, 2023, 10:33 pm
Zyversa therapeutics announces research published in the journal of clinical investigation reinforcing ic 100’s rationale for inhibiting asc specks to attenuate spread of inflammation into surrounding
Patients with chronic kidney disease (“CKD”) exhibit chronic systemic inflammation characterized by...
September 22, 2023, 10:35 am
Frontier portfolio company signs collaboration deal with merck
Frontier IP Group PLC (AIM:FIPP), a firm specialising in the commercialisation of intellectual property, announced in an RNS today that its portfolio ...
September 21, 2023, 4:01 am
Exscientia stock surges on merck kgaa partnership
Exscientia PLC shares climbed as much as 30% in pre-market trading on Wednesday after the precision-medicine company announced a new, multi-year coll...
September 20, 2023, 9:13 am
Exscientia's stock rockets toward a record gain after ai-driven drug discovery collaboration with germany's merck kgaa
The U.S.-listed shares of Exscientia PLC EXAI soared 28.5% toward a record one-day gain, and enough to pace all premarket gainers on major U.S. exchan...
September 20, 2023, 7:50 am
Zyversa therapeutics announces research published in frontiers in immunology reinforcing ic 100’s rationale for inhibiting multiple inflammasomes to control inflammation in various inflammatory diseas
Activation of multiple inflammasome pathways contributes to pathological inflammation in neurodegenerat...
September 12, 2023, 10:30 am
Anaptysbio to present at the stifel 2023 immunology and inflammation virtual summit
SAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative...
September 12, 2023, 9:15 am
Biovie presents alzheimer's study data on patient's baseline characteristics
BioVie Inc (NASDAQ:BIVI) has unveiled early data from its Phase 3 study of its investigational drug NE3107 in patients with mild to moderate Alzheimer...
September 11, 2023, 8:42 am
